Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Activating Thermoplastic Polyurethane Surfaces with Poly(ethylene glycol)-Based Recombinant Human α‑Defensin 5 Monolayers for Antibiofilm Activity

  • Rodríguez Rodríguez, Xavier
  • López-Cano, Adrià
  • Mayolo-Deloisa, Karla
  • Pich, Oscar Q.
  • Bierge, Paula
  • Ventosa, Nora
  • García-de-la-Maria, Cristina
  • Miró, José M.
  • Gasch, Oriol
  • Veciana, Jaume
  • Guasch, Judith
  • Arís, Anna
  • Garcia-Fruitos, Elena
  • Ratera, Imma
  • FUNCATH
Addressing multidrug-resistant microbial infections linked to implantable biomedical devices is an urgent need. In recent years, there has been an active exploration of different surface coatings to prevent and combat drug-resistant microbes. In this research, we present a facile chemical modification of thermoplastic polyurethane (TPU) surfaces with poly(ethylene glycol)-based recombinant human α-defensin 5 (HD5) protein with antimicrobial activity. TPU is one of the most relevant materials used for medical devices with good mechanical properties but also good chemical resistance, which makes it difficult to modify. The chemical modification of TPU surfaces is achieved via a three-step procedure based on (i) TPU activation using hexamethylene diisocyanate (HDI); (ii) interfacial reaction with poly(ethylene glycol) (PEG) derivatives; and finally, (iii) a facile click reaction between the PEG-maleimide terminated assembled monolayers on the TPU and the cysteine (-thiol) termination of the recently designed recombinant human α-defensin 5 (HD5) protein. The obtained PEG based HD5 assembled monolayers on TPU were characterized using a surface science multitechnique approach including scanning electron microscopy, atomic force microscopy, contact angle, and X-ray photoelectron spectroscopy. The modified TPU surfaces with the HD5 protein derivative exhibit broad-spectrum antibacterial properties reducing biofilm formation against Pseudomonas aeruginosa (Gram-negative), methicillin-resistant Staphylococcus aureus (MRSA) (Gram-positive) and methicillin-resistant Staphylococcus epidermidis (MRSE) (Gram-positive). These findings underscore the substantial potential of protein-modified TPU surfaces for applications in combating bacterial infections associated with implantable materials and devices., Financial support by the MICIU of Spain (projects PID2019105622RBI00, PID2020-115296RA-I00, PID2022-137332OBI00, CEX2019-000917-S, CEX2023- 001263-S), CSIC (project 2023AEP092), the Marató de TV3 foundation (project number 201812-30-31-32-33 and 202326-30-31-32-33), and the Generalitat de Catalunya (project SGR Cat 2021-00438 and 2021-01552) is acknowledged. The authors are also grateful for the financial support received from Instituto de Salud Carlos III and the Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBERBBN). J.G. is grateful to the Max Planck Institute for Medical Research (Heidelberg, Germany) for their collaboration through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy”. ICMAB-CSIC acknowledges support from the Severo Ochoa Programme for Centres of Excellence in R&D (FUNFUTURE, CEX2019-000917-S). J.M.M. received a personal 80:20 research grant from the Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017−24. This work has been developed inside the Materials Science PhD program of Universitat Autonoma de Barcelona. X.R.R. was supported by a grant PTA2021-020955-I funded by MCIN/AEI/10.13039/ 501100011033 and the FSE. This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 801342 (Tecniospring INDUSTRY) and the Government of Catalonia’s Agency for Business Competitiveness (ACCIO; TECSPR19-1-0065). A.L.-C. received a predoctoral fellowship from Generalitat de Catalunya (FIAGAUR), and P.B. was supported by a PFIS predoctoral fellowship (FI20/00009) from the Instituto de Salud Carlos III. The authors also acknowledge the ICTS NANBIOSIS for the support of the Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (https://www.nanbiosis.es/ portfolio/u6-biomaterial-processing-and-nanostructuring-unit/, info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activating Thermoplastic Polyurethane Surfaces with Poly(ethylene glycol)-Based Recombinant Human α-Defensin 5 Monolayers for Antibiofilm Activity

  • Rodríguez Rodríguez, Xavier
  • López Cano, Adrià
  • Mayolo Deloisa, Karla P.
  • Pich, Oscar Q.
  • Bierge, Paula
  • Ventosa, Nora
  • García-de-la-Maria, Cristina
  • Miró, José M.
  • Gasch, Oriol
  • Veciana, Jaume
  • Guasch, Judith
  • Arís, Anna
  • Garcia Fruitós, Elena
  • Ratera, Immaculada
Addressing multidrug-resistant microbial infections linked to implantable biomedical devices is an urgent need. In recent years, there has been an active exploration of different surface coatings to prevent and combat drug-resistant microbes. In this research, we present a facile chemical modification of thermoplastic polyurethane (TPU) surfaces with poly(ethylene glycol)-based recombinant human α-defensin 5 (HD5) protein with antimicrobial activity. TPU is one of the most relevant materials used for medical devices with good mechanical properties but also good chemical resistance, which makes it difficult to modify. The chemical modification of TPU surfaces is achieved via a three-step procedure based on (i) TPU activation using hexamethylene diisocyanate (HDI); (ii) interfacial reaction with poly(ethylene glycol) (PEG) derivatives; and finally, (iii) a facile click reaction between the PEG-maleimide terminated assembled monolayers on the TPU and the cysteine (-thiol) termination of the recently designed recombinant human α-defensin 5 (HD5) protein. The obtained PEG based HD5 assembled monolayers on TPU were characterized using a surface science multitechnique approach including scanning electron microscopy, atomic force microscopy, contact angle, and X-ray photoelectron spectroscopy. The modified TPU surfaces with the HD5 protein derivative exhibit broad-spectrum antibacterial properties reducing biofilm formation against Pseudomonas aeruginosa (Gram-negative), methicillin-resistant Staphylococcus aureus (MRSA) (Gram-positive) and methicillin-resistant Staphylococcus epidermidis (MRSE) (Gram-positive). These findings underscore the substantial potential of protein-modified TPU surfaces for applications in combating bacterial infections associated with implantable materials and devices., Financial support by the MICIU of Spain (projects PID2019-105622RBI00, PID2020-115296RA-I00, PID2022-137332OB-I00, CEX2019-000917-S, CEX2023- 001263-S), CSIC (project 2023AEP092), the Marató de TV3 foundation (project number 201812-30-31-32-33 and 202326-30-31-32-33), and the Generalitat de Catalunya (project SGR Cat 2021-00438 and 2021-01552) is acknowledged. The authors are also grateful for the financial support received from Instituto de Salud Carlos III and the Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN). J.G. is grateful to the Max Planck Institute for Medical Research (Heidelberg, Germany) for their collaboration through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy”. ICMAB-CSIC acknowledges support from the Severo Ochoa Programme for Centres of Excellence in R&D (FUNFUTURE, CEX2019-000917-S). J.M.M. received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–24. This work has been developed inside the Materials Science PhD program of Universitat Autonoma de Barcelona. X.R.R. was supported by a grant PTA2021-020955-I funded by MCIN/AEI/10.13039/501100011033 and the FSE. This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 801342 (Tecniospring INDUSTRY) and the Government of Catalonia’s Agency for Business Competitiveness (ACCIO; TECSPR19-1-0065). A.L.-C. received a predoctoral fellowship from Generalitat de Catalunya (FI-AGAUR), and P.B. was supported by a PFIS predoctoral fellowship (FI20/00009) from the Instituto de Salud Carlos III. The authors also acknowledge the ICTS NANBIOSIS for the support of the Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (https://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S). With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Activating Thermoplastic Polyurethane Surfaces with Poly(ethylene glycol)-Based Recombinant Human α‑Defensin 5 Monolayers for Antibiofilm Activity

  • Rodríguez Rodríguez, Xavier
  • López-Cano, Adrià
  • Mayolo-Deloisa, Karla
  • Pich, Oscar Q.
  • Bierge, Paula
  • Ventosa, Nora
  • García-de-la-Maria, Cristina
  • Miró, José M.
  • Gasch, Oriol
  • Veciana, Jaume
  • Guasch, Judith
  • Arís, Anna
  • Garcia-Fruitos, Elena
  • Ratera, Imma
  • FUNCATH
Addressing multidrug-resistant microbial infections linked to implantable biomedical devices is an urgent need. In recent years, there has been an active exploration of different surface coatings to prevent and combat drug-resistant microbes. In this research, we present a facile chemical modification of thermoplastic polyurethane (TPU) surfaces with poly(ethylene glycol)-based recombinant human α-defensin 5 (HD5) protein with antimicrobial activity. TPU is one of the most relevant materials used for medical devices with good mechanical properties but also good chemical resistance, which makes it difficult to modify. The chemical modification of TPU surfaces is achieved via a three-step procedure based on (i) TPU activation using hexamethylene diisocyanate (HDI); (ii) interfacial reaction with poly(ethylene glycol) (PEG) derivatives; and finally, (iii) a facile click reaction between the PEG-maleimide terminated assembled monolayers on the TPU and the cysteine (-thiol) termination of the recently designed recombinant human α-defensin 5 (HD5) protein. The obtained PEG based HD5 assembled monolayers on TPU were characterized using a surface science multitechnique approach including scanning electron microscopy, atomic force microscopy, contact angle, and X-ray photoelectron spectroscopy. The modified TPU surfaces with the HD5 protein derivative exhibit broad-spectrum antibacterial properties reducing biofilm formation against Pseudomonas aeruginosa (Gram-negative), methicillin-resistant Staphylococcus aureus (MRSA) (Gram-positive) and methicillin-resistant Staphylococcus epidermidis (MRSE) (Gram-positive). These findings underscore the substantial potential of protein-modified TPU surfaces for applications in combating bacterial infections associated with implantable materials and devices., Financial support by the MICIU of Spain (projects PID2019105622RBI00, PID2020-115296RA-I00, PID2022-137332OBI00, CEX2019-000917-S, CEX2023- 001263-S), CSIC (project 2023AEP092), the Marató de TV3 foundation (project number 201812-30-31-32-33 and 202326-30-31-32-33), and the Generalitat de Catalunya (project SGR Cat 2021-00438 and 2021-01552) is acknowledged. The authors are also grateful for the financial support received from Instituto de Salud Carlos III and the Networking Research Center on Bioengineering, Biomaterials, and Nanomedicine (CIBERBBN). J.G. is grateful to the Max Planck Institute for Medical Research (Heidelberg, Germany) for their collaboration through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy”. ICMAB-CSIC acknowledges support from the Severo Ochoa Programme for Centres of Excellence in R&D (FUNFUTURE, CEX2019-000917-S). J.M.M. received a personal 80:20 research grant from the Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017−24. This work has been developed inside the Materials Science PhD program of Universitat Autonoma de Barcelona. X.R.R. was supported by a grant PTA2021-020955-I funded by MCIN/AEI/10.13039/ 501100011033 and the FSE. This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 801342 (Tecniospring INDUSTRY) and the Government of Catalonia’s Agency for Business Competitiveness (ACCIO; TECSPR19-1-0065). A.L.-C. received a predoctoral fellowship from Generalitat de Catalunya (FIAGAUR), and P.B. was supported by a PFIS predoctoral fellowship (FI20/00009) from the Instituto de Salud Carlos III. The authors also acknowledge the ICTS NANBIOSIS for the support of the Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (https://www.nanbiosis.es/ portfolio/u6-biomaterial-processing-and-nanostructuring-unit/, info:eu-repo/semantics/publishedVersion